Looking to acquire companies and
launch new products in India: Lupin
Homegrown drug major Lupin
is looking to acquire companies and launch new products in the domestic market
as it aims to scale up its Indian operations.
The Mumbai-based firm,
which is the fifth largest generic player in the US market, has so far stayed
away from inorganic growth in India where it clocked revenues of Rs 2,479 crore
in the previous fiscal.
The company is looking at
ramping up its India business, with new product launches aided by strategic
in-licensing alliances, Lupin Group President Shakti Chakraborty told PTI.
He added: "The
company is also looking at acquisitions within the market which Lupin hasn't
done so far in India."
Growth in various
therapeutic segments including dermatology and oncology could be fuelled in the
domestic market by acquisitions and alliances, he said.
"While Lupin is
strengthening its leadership credentials in cardiovascular, diabetes,
respiratory segments the growth in niche segments like dermatology, ophthalmology and oncology
could be fuelled by such arrangements be it in-licensing, alliances or outright
acquisitions," Chakraborty said.
He, however, did not share
further details. Commenting on the revenue growth of Indian
No comments:
Post a Comment